Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
3.45
USD
|
+2.99%
|
|
+7.81%
|
-52.74%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,261
|
880.2
|
617.3
|
307.5
|
146.4
|
-
|
-
|
Enterprise Value (EV)
1 |
927.3
|
538.3
|
273.3
|
83.92
|
-83.04
|
-178.6
|
146.4
|
P/E ratio
|
-12.9
x
|
-7.45
x
|
-21.3
x
|
-3.27
x
|
-1.29
x
|
-1.1
x
|
-0.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9,341
x
|
116
x
|
4.68
x
|
6.01
x
|
3.24
x
|
12.4
x
|
3.97
x
|
EV / Revenue
|
6,869
x
|
70.8
x
|
2.07
x
|
1.64
x
|
-1.84
x
|
-15.1
x
|
3.97
x
|
EV / EBITDA
|
-17.4
x
|
-5.02
x
|
-15.3
x
|
-0.73
x
|
0.66
x
|
0.98
x
|
-1.2
x
|
EV / FCF
|
-119
x
|
-6.15
x
|
-976
x
|
-0.65
x
|
1.06
x
|
1.4
x
|
-1.13
x
|
FCF Yield
|
-0.84%
|
-16.3%
|
-0.1%
|
-154%
|
93.9%
|
71.7%
|
-88.8%
|
Price to Book
|
4.41
x
|
3.06
x
|
2.21
x
|
1.45
x
|
0.54
x
|
0.52
x
|
-
|
Nbr of stocks (in thousands)
|
36,765
|
41,735
|
41,962
|
42,130
|
42,445
|
-
|
-
|
Reference price
2 |
34.30
|
21.09
|
14.71
|
7.300
|
3.450
|
3.450
|
3.450
|
Announcement Date
|
04/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.135
|
7.6
|
131.8
|
51.13
|
45.21
|
11.79
|
36.86
|
EBITDA
1 |
-
|
-53.4
|
-107.2
|
-17.82
|
-114.3
|
-126.2
|
-181.8
|
-121.9
|
EBIT
1 |
-
|
-54.3
|
-108.7
|
-19.8
|
-116.2
|
-126.4
|
-168.3
|
-164.7
|
Operating Margin
|
-
|
-40,223.7%
|
-1,429.74%
|
-15.02%
|
-227.3%
|
-279.56%
|
-1,427.23%
|
-446.78%
|
Earnings before Tax (EBT)
1 |
-
|
-54.74
|
-108.6
|
-13.9
|
-103.2
|
-118.9
|
-170.8
|
-169.5
|
Net income
1 |
-27.22
|
-53.42
|
-106.9
|
-29.05
|
-93.8
|
-115.9
|
-170.8
|
-169.5
|
Net margin
|
-
|
-39,568.15%
|
-1,406.68%
|
-22.03%
|
-183.44%
|
-256.29%
|
-1,448.03%
|
-459.81%
|
EPS
2 |
-
|
-2.660
|
-2.830
|
-0.6900
|
-2.230
|
-2.677
|
-3.135
|
-3.705
|
Free Cash Flow
1 |
-
|
-7.805
|
-87.49
|
-0.28
|
-129.1
|
-78
|
-128
|
-130
|
FCF margin
|
-
|
-5,781.48%
|
-1,151.13%
|
-0.21%
|
-252.47%
|
-172.52%
|
-1,085.43%
|
-352.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/05/20
|
04/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.278
|
6.877
|
0.408
|
0.679
|
112.5
|
18.2
|
5.678
|
30.25
|
2.159
|
13.05
|
38.4
|
2.404
|
2.571
|
2.908
|
4.703
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-31.68
|
-28.73
|
-34.83
|
-38.73
|
73.4
|
-19.63
|
-34.68
|
-12.26
|
-38.42
|
-30.87
|
-4.599
|
-40.97
|
-41.03
|
-41.3
|
-39.42
|
Operating Margin
|
-11,395.32%
|
-417.83%
|
-8,536.52%
|
-5,704.57%
|
65.22%
|
-107.88%
|
-610.8%
|
-40.52%
|
-1,779.43%
|
-236.58%
|
-11.98%
|
-1,704.28%
|
-1,595.87%
|
-1,419.93%
|
-838.27%
|
Earnings before Tax (EBT)
1 |
-31.6
|
-28.7
|
-34.72
|
-38.06
|
75.52
|
-16.63
|
-31.32
|
-8.836
|
-35.18
|
-27.84
|
-3.682
|
-38.4
|
-38.8
|
-39.42
|
-38.29
|
Net income
1 |
-30.89
|
-28.29
|
-34.76
|
-38.09
|
75.46
|
-31.66
|
-34.94
|
-11.95
|
-18.88
|
-28.03
|
-2.342
|
-38.15
|
-38.55
|
-39.18
|
-38.29
|
Net margin
|
-11,112.23%
|
-411.37%
|
-8,518.87%
|
-5,610.16%
|
67.05%
|
-173.96%
|
-615.38%
|
-39.49%
|
-874.43%
|
-214.84%
|
-6.1%
|
-1,586.89%
|
-1,499.68%
|
-1,346.99%
|
-814.22%
|
EPS
2 |
-0.8300
|
-0.7100
|
-0.8300
|
-0.9100
|
1.710
|
-0.7500
|
-0.8300
|
-0.2800
|
-0.4500
|
-0.6700
|
-0.0160
|
-0.8860
|
-0.8980
|
-0.8960
|
-0.8900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
01/03/22
|
05/05/22
|
04/08/22
|
09/11/22
|
28/02/23
|
09/05/23
|
09/08/23
|
09/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
334
|
342
|
344
|
224
|
229
|
325
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-7.81
|
-87.5
|
-0.28
|
-129
|
-78
|
-128
|
-130
|
ROE (net income / shareholders' equity)
|
-
|
-44.4%
|
-37.2%
|
-10.2%
|
-38.2%
|
-43%
|
-48.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.770
|
6.890
|
6.650
|
5.030
|
6.400
|
6.630
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.24
|
1.69
|
0.6
|
1.94
|
1
|
1
|
5
|
Capex / Sales
|
-
|
1,657.04%
|
22.24%
|
0.46%
|
3.79%
|
2.21%
|
8.48%
|
13.57%
|
Announcement Date
|
29/05/20
|
04/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
3.45
USD Average target price
15.33
USD Spread / Average Target +344.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -52.74% | 146M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|